✦ LIBER ✦

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis

✍ Scribed by Cella, D; Michaelson, M D; Bushmakin, A G; Cappelleri, J C; Charbonneau, C; Kim, S T; Li, J Z; Motzer, R J

Book ID: 110000353
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 303 KB
Volume: 102
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6605552

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II trial of intravenous gemcitab

A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma

✍ Christopher W. Ryan; Nicholas J. Vogelzang; Walter M. Stadler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous‐infusion 5‐fluorouracil (5‐FU) in combination with subcutaneous interleukin‐2 (IL2) and interferon‐α (IFNA) in patients with metastatic renal cell carcinoma. ## METH

Improved tolerability and quality of lif

Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2b : Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-α-2b in patients with metastatic renal cell carcinoma

✍ Nizar M. Tannir; Lorenzo Cohen; Xuemei Wang; Peter Thall; Paul F. Mathew; Eric J 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

Subcutaneous interleukin-2 and interfero

Subcutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin-2 and interferon α : Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie

✍ Alain Ravaud; Rémy Delva; Fréderic Gomez; Christine Chevreau; Jean-Yves Douillar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Background: The main objective of this trial was to evaluate the combination of subcutaneous (sc) interleukin-2 (il-2) with interferon alpha-2a (ifn-alpha) in the treatment of patients with metastatic renal cell carcinoma (mrcc) compared with a previous trial that used continuous-infusion il-2 a

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin